Aim: To examine the influence of the black currant anthocyanins (BCACs) on the disease progression of open-angle glaucoma (OAG), a randomized, placebo-controlled, double-masked trial was made in 38 patients with OAG treated by antiglaucoma drops. Methods: BCACs (50 mg/day, n = 19) or their placebos (n = 19) were orally administered once daily for a 24-month period. Systemic blood pressure, pulse rates, intraocular pressure (IOP), ocular blood circulation by laser-speckle flowgraphy, and Humphrey visual field mean deviation (MD) were measured during the 24-month period. Results: As a main outcome measurement, we evaluated the difference between the groups in MD deterioration in the eye with a better MD from the trial’s baseline through 24 months. A statistically significant difference was observed between the treatment groups in mean change from baseline in MD 24 months after therapy (p = 0.039, unpaired t test). Upon administration of BCACs, the ocular blood flows during the 24-month observational period increased in comparison with placebo-treated patients. However, no significant changes were observed in systemic and ocular conditions including IOP during the 24-month period. Conclusions: Our results suggest that oral administration of BCACs may be a safe and promising supplement for patients with OAG in addition to antiglaucoma medication.

Shields MB: An overview of glaucoma; in Shields MB (ed): Textbook of Glaucoma, ed 4. Baltimore, Williams & Wilkins, 1988, pp 1–2.
Collaborative Normal-Tension Glaucoma Study Group: Comparison of glaucomatous progression between untreated patients with normal-tension glaucoma and patients with therapeutically reduced intraocular pressures. Am J Ophthalmol 1998;126:487–497.
Collaborative Normal-Tension Glaucoma Study Group: The effectiveness of intraocular pressure reduction in the treatment of normal-tension glaucoma. Am J Ophthalmol 1998;126:498–505.
The AGIS Investigators: The Advanced Glaucoma Intervention Study (AIGIS). 7. The relationship between control of intraocular pressure and visual field deterioration. Am J Ophthalmol 2000;130:429–440.
Kass MA, Heuer DK, Higginbotham EJ, Johnson CA, Keltner JL, Miller JP, Parrish RK, Wilson MR, Gordon MO: The Ocular Hypertension Treatment Study: a randomized trial determines that topical ocular hypotensive medication delays or prevents the onset of primary open-angle glaucoma. Arch Ophthalmol 2002;120:701–713.
Kitazawa Y, Shirato S, Yamamoto T: Optic disc hemorrhage in low-tension glaucoma. Ophthalmology 1986;93:853–857.
Leske MC, Heijl A, Hussein M, Bengtsson B, Hyman L, Komaroff E, Early Manifest Glaucoma Trial Group: Factors for glaucoma progression and the effect of treatment: the Early Manifest Glaucoma Trial. Arch Ophthalmol 2003;121:48–56.
Barry CJ, Cooper RL, Eikelboom RH: Optic disc hemorrhages and vascular abnormalities in a glaucoma population. Aust NZ J Ophthalmol 1997;25:137–144.
Hirota A, Mishima HK, Kiuchi Y: Incidence of retinal vein occlusion at the glaucoma clinic of Hiroshima University. Ophthalmologica 1997;211:288–291.
Jonas JB, Naumann GO: Parapapillary retinal vessel diameter in normal and glaucoma eyes. II. Correlations. Invest Ophthalmol Vis Sci 1989;30:1604–1611.
Ogawa T, Ogawa A, So K: Target intraocular pressure and risk factors for progression of visual field loss in primary open-angle glaucoma. Nippon Ganka Gakkai Zasshi 2002;106:488–493.
Ohguro I, Ohguro H, Ohkuro H, Nakazawa M: Study of contribution of low level of plasma endothelin-1 concentration to pathogenesis of glaucomatous optic neuropathy. Hirosaki Med J 2006;57:59–64.
Ohguro I, Yamamoto Y, Takeuchi K, Ohguro H, Matsumoto M, Matsuhashi H, Nakazawa M: Relation between platelet aggregation rate and pathogenesis of glaucomatous optic neuropathy. J Eye 2005;22:669–672.
Renaud S, de Logeril M: Wine, alcohol, platelets, and the French paradox for coronary heart disease. Lancet 1992;339:1523–1526.
Nakaishi H, Matsumoto H, Tominaga S, Hirayama M: Effects of blackcurrant anthocyanoides intake on dark adaptation and VDT work-induced transient refractive alternation in healthy humans. Altern Med Rev 2000;5:553–562.
Matsumoto H, Kamm KE, Stull JT, Azuma H: Delphinidine-3-rutiniside relaxes the bovine ciliary smooth muscle through activation of ETB receptor and NO/cGMP pathway. Exp Eye Res 2005;80:313–322.
Haefliger IO, Flammer J, Bény JL, Lüscher TF: Endothelium-dependent vasoactive modulation in the ophthalmic circulation. Prog Retin Eye Res 2001;20:209–225.
Ohguro I, Ohguro H, Nakazawa M: Effects of anthocyanins in black currant on retinal blood flow circulation of patients with normal tension glaucoma. A pilot study. Hirosaki Med J 2007;59:23–32.
Anderson DR, Patella VM: Interpretation of a single field; in Anderson DR (ed): Automated Static Perimetry, ed 2. St Louis, Mosby, 1999, pp 121–190.
Koseki N, Araie M, Tomidokoro A, Nagahara M, Hasegawa T, Tamaki Y, Yamamoto S: A placebo-controlled 3-years study of a calcium blocker on visual field and ocular circulation in glaucoma with low-normal pressure. Ophthalmology 2008;115:2049–2057.
Advanced Glaucoma Intervention Study. 2. Visual field test scoring and reliability. Ophthalmology 1994;101:1445–1455.
Ohguro I, Katai M, Tanaka S, Tsuruta M, Ohguro H: Blood flow in the optic nerve head following instillation of 1% dorzolamide in eyes with glaucoma. Jpn J Clin Ophthalmol 2010;64:921–926.
Logan JF, Rankin SJ, Jackson AJ: Retinal blood flow measurements and neuroretinal rim damage in glaucoma. Br J Ophthalmol 2004;88:1049–1054.
Yaoeda K, Shirakashi M, Fukushima A, Funaki S, Funaki H, Abe H, Tanabe N: Relationship between optic nerve microcirculation and visual field loss in glaucoma. Acta Ophthalmol Scand 2003;81:253–259.
Sato EA, Ohtake Y, Shinoda K, Mashima Y, Kimura I: Decreased blood flow at neuroretinal rim of optic nerve head corresponds with visual field deficit in eyes with normal tension glaucoma. Graefes Arch Clin Exp Ophthalmol 2006;244:795–801.
Hafez AS, Bizzarro RLG, Lesk MR: Evaluation of optic nerve head and peripapillary retinal blood flow in glaucoma patients, ocular hypertensive, and normal subjects. Am J Ophthalmol 2003;136:1022–1031.
Jonas JB, Gusek GC, Naumann GO: Optic disc, cup and neuroretinal rim size, configuration and correlation in normal eyes. Invest Ophthalmol Vis Sci 1988;29:1151–1158.
Harris A, Ishii Y, Chung HS, Jonescu-Cuypers CP, McCranor LJ, Kagemann L, Garzozi HJ: Blood flow per unit retinal nerve fiber tissue volume is lower in the human inferior retina. Br J Ophthalmol 2003;87:184–188.
Hart WM, Becker B: The onset and evolution of glaucomatous visual field defect. Ophthalmology 1982;89:268–279.
McGhie TK, Walton MC: The bioavailability and absorption of anthocyanins: towards a better understanding. Mol Nutr Food Res 2007;51:702–713.
Moller P, Loft S, Alfthan G, Freese R: Oxidative DNA damage in circulating mononuclear blood cells after ingestion of black currant juice or anthocyanins-rich drink. Mutat Res 2004;551:119–126.
Hirschberg Y, Shackelford A, Mascioli EA, Babayan VK, Bistrian BR, Blackburn GL: The response to endotoxin in guinea-pigs after intravenous blackcurrant seed oil. Lipid 1990;25:491–496.
Kamazawa Y, Kawaguchi K, Takimoto H: Immunomodulating effects of flavonoids on acute and chronic inflammatory responses caused by tumor necrosis factor alpha. Curr Pharma Des 2006;12:4271–4279.
Matsumoto H, Inaba H, Kishi M, Tominaga S, Hirayama M, Tsuda T: Orally administered delphinidin 3-rutinoside and cyanidin 3-rutinoside are directly absorbed in rats and humans and appear in the blood as the intact forms. J Agric Food Chem 2001;49:1546–1551.
Matsumoto H, Nakamura Y, Iida H, Ito K, Ohguro H: Comparative assessment of distribution of black currant anthocyanins in rabbit and rat ocular tissues. Exp Eye Res 2006;83:348–356.
Matsumoto H, Nakamura Y, Tachibanaki S, Kawamura S, Hirayama M: Stimulatory effect of cyanidine 3-glycosides on the regeneration of rhodopsin. J Agric Food Chem 2003;51:3560–3563.
Iida H, Nakamura Y, Matsumoto H, Takeuchi Y, Harano S, Ishihara M, Katsumi O: Effect of black-currant extract on negative lens-induced ocular growth in chicks. Ophthalmic Res 2010;44:242–250.
MacCumber MW, D’Anna SA: Endothelin receptor-binding subtypes in the human retina and choroid. Arch Ophthalmol 1994;112:1231–1235.
Ripodas A, de Juan JA, Roldán-Pallarés M, Bernal R, Moya J, Chao M, López A, Fernández-Cruz A, Fernández-Durango R: Localization of endothelin-1 mRNA expression and immunoreactivity in the retina and optic nerve from human and porcine eye. Evidence for endothelin-1 expression in astrocytes. Brain Res 2001;912:137–143.
Oku H, Kida T, Sugiyama T, Hamada J, Sato B, Ikeda T: Possible involvement of endothelin-1 and nitric oxide in the pathogenesis of proliferative diabetic retinopathy. Retina 2001;21:647–651.
Stangos AN, Petropoulos IK, Pournaras JA, Mendrinos E, Pournaras CJ: The vasodilatory effect of juxta-arteriolar microinjection of endothelin A receptor inhibitor in healthy and acute branch retinal vein occlusion mini pig retinas. Invest Ophthalmol Vis Sci 2010;51:2185–2190.
Kaiser HJ, Flammer J, Wenk M, Luschur T: Endothelin-1 plasma levels in normal-tension glaucoma. Abnormal response to postural changes. Graefes Arch Clin Exp Ophthalmol 1995;233:484–488.
Nicolela MT, Ferrier SN, Morrison CA, Archibald ML, Le Vatte TL, Wallace K, Chauhan BC, Le Blanc RP: Effects of cold-induced vasospasm in glaucoma: the role of endothelin-1. Invest Ophthalmol Vis Sci 2003;4:2565–2572.
Venkataraman ST, Flanagan JG, Hudson C: Vascular reactivity of optic nerve head and retinal blood vessels in glaucoma. Microcirculation 2010;17:568–581.
Good TJ, Kahook MY: The role of endothelin in the pathophysiology of glaucoma. Expert Opin Ther Targets 2010;14:647–654.
Cellini M, Possati GL, Profazio V, Sbrocca M, Caramazza N, Caramazza R: Color Doppler imaging and plasma levels of endothelin-1 in low-tension glaucoma. Acta Ophthalmol Scand 1997;224:S11–S13.
Kaiser HJ, Flammer J, Wenk M, Luschur T: Endothelin-1 plasma levels in normal-tension glaucoma. Abnormal response to postural changes. Graefes Arch Clin Exp Ophthalmol 1995;233:484–488.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.